RenovoRx

A recently published peer-reviewed case study from researchers at Moffitt Cancer Center found PET-CT imaging, rather than CT alone, showed a meaningful reduction in tumor metabolic activity after treatment, suggesting that PET may improve monitoring of therapeutic response following treatment delivered via TAMP. Find details: https://bit.ly/4owgpft

RenovoRx Chief Clinical Officer, Leesa Gentry, will participate in a panel at San Francisco tomorrow, June 11th at 10:30–11:15 AM PT, on “Beyond the AI Hype: What Actually Changes in Clinical Development.” The discussion will focus on practical AI adoption in clinical research, including improved efficiency, earlier risk detection, governance, and responsible implementation in regulated environments. Learn more: https://bit.ly/49TTbtF